Aditi Hazra, Assistant Director at VA COURAGE and Assistant Professor at Harvard Medical School, shared on LinkedIn:
“Honored to be recognized among the 100 Influential Women in Oncology 2026.
From to neighborhoods to nations, my research examines hidden heterogeneity in cancer: across molecular subtypes, stage (such as advanced inflammatory breast cancer or DCIS), populations, communities, and health systems.
My goal is not only to discover genes or molecular signatures, but to ask who is represented in the science, who benefits from precision oncology, and who remains invisible to it.
Through doctoral training in cancer biology, postdoctoral training in molecular and genetic epidemiology, and coursework in computer vision for AI, I aim to make the invisible visible and the historically invisible included.
I am grateful to OncoDaily for the recognition and to my colleagues, collaborators, patients, Veterans, refugee communities, mentors, trainees, and supporters who make this work possible!
I am also grateful to have been mentored by Dr. Beth Mittendorf on unraveling the breast tumor microenvironment;
- to have connected with Isabel Mestres and the City Cancer Challenge team around their work across cities and the humanitarian opportunity to include citizens as well as refugees;
- to have met Dr. Beatrice Wiafe Addai, and to be a part of the Breast Oncology Program led by Dr. Sara Tolaney at DFCI.
Most recently, I had the honor of meeting H.E. Fatima Maada Bio and learning from her leadership in building capacity for cancer care in Sierra Leone and transforming lived experience into global consensus on the elimination of child marriage.
To be recognized alongside women advancing oncology across discovery, clinical care, advocacy, policy, implementation, and global health is humbling and inspiring.
Heterogeneity is not noise. Often, it is the spatial signal.”
You can also read:
